Physician profile
Ramon Thomas
NPI 1417025479
$14,415.32
in general payments reported to CMS, 2019-2025
35 companies · $3,231 in 2025
The $3,231 reported for 2025 was more than what 96% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $717 · 2020: $197 · 2021: $337 · 2022: $689 · 2023: $379 · 2024: $8,866 · 2025: $3,231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $5,500 · Travel and Lodging: $5,452 · Food and Beverage: $1,515 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $5,500.00 |
| Travel and Lodging | $5,451.99 |
| Food and Beverage | $1,515.01 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $11,949.46 | 2024-2025 | |
| Abbvie INC. | $442.38 | 2019-2022 | |
| Ethicon US, LLC | $295.82 | 2019-2023 | Harmonic, Ethicon, Stratafix |
| Gynesonics, INC. | $243.09 | 2022-2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Sanara Medtech INC. | $198.10 | 2022 | |
| Medtronic, INC. | $174.96 | 2022 | |
| Avion Pharmaceuticals | $106.03 | 2019-2023 | Balcoltra |
| Hologic Sales and Service, LLC | $102.50 | 2019-2025 | Thinprep 2000 Processor, Aptima, Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Medical Device Business Services, INC. | $78.07 | 2019 | |
| Exeltis, USA INC. | $77.21 | 2020-2025 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $76.34 | 2019-2021 | |
| Myovant Sciences INC. | $70.11 | 2021-2022 | |
| Pfizer INC. | $65.88 | 2019-2023 | |
| Therapeuticsmd, INC. | $64.24 | 2019-2020 | |
| Astellas Pharma US INC | $53.86 | 2019-2025 | Veozah |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $40.95 | 2021-2022 | |
| Biogen, INC. | $33.83 | 2025 | Zurzuvae |
| Amag Pharmaceuticals, INC. | $32.56 | 2019 | |
| Becton, Dickinson and Company | $30.62 | 2023 | Bd Onclarity |
| Daiichi Sankyo INC. | $28.52 | 2019 | |
| Allergan, INC. | $27.50 | 2019 | |
| Merck Sharp & Dohme LLC | $26.69 | 2019-2020 | |
| Duchesnay USA Incorporated | $25.59 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.82 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $16.26 | 2025 | Exparel |
| Sage Therapeutics, LLC | $15.95 | 2020 | |
| Lupin INC. | $15.63 | 2019 | |
| Aspira Women'S Health INC | $15.23 | 2020 | |
| Davol INC. | $15.15 | 2022 | |
| Coopersurgical, INC. | $14.77 | 2019 | |
| Smith+Nephew, INC. | $14.34 | 2021 | |
| Axonics, INC. | $13.57 | 2021 | |
| Dysis Medical, INC. | $12.64 | 2021 | |
| Minerva Surgical, INC | $10.79 | 2019 | |
| Organon LLC | $9.86 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramon Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.